Open this publication in new window or tab >>Department of Internal Medicine, Ersta Hospital, Stockholm, Sweden; Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden.
Department of Gastroenterology, County Council of Östergötland, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Department of Medical Sciences, Gastroenterology Research Group, Uppsala University, Uppsala, Sweden.
Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastroenterology.
Department of Gastroenterology, Skåne University Hospital, Malmö/Lund, Sweden.
Department of Medicine, Geriatrics and Emergency Medicine, Sahlgrenska University Hospital, Östra Hospital, Gothenburg, Sweden.
Department of Gastroenterology, Skåne University Hospital, Malmö/Lund, Sweden.
Örebro University, School of Medical Sciences.
School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Örebro University, School of Medical Sciences.
Örebro University, School of Medical Sciences.
Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Department of Medicine and Surgery, LUM University, Casamassima, Italy; Gastrointestinal Genetics Lab, CIC bioGUNE - BRTA, Derio, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain.
Örebro University, School of Medical Sciences.
Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Department of Surgery, Linköping University, Linköping, Sweden.
Department of Medical Sciences, Gastroenterology Research Group, Uppsala University, Uppsala, Sweden.
Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
Örebro University, School of Medical Sciences. Department of Clinical Research Laboratory, Faculty of Medicine and Health, Örebro University, Örebro, Sweden .
Örebro University, School of Medical Sciences. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden .
Show others...
2025 (English)In: BMJ Open, E-ISSN 2044-6055, Vol. 15, no 5, article id e099218Article in journal (Refereed) Published
Abstract [en]
Purpose: There is a need for diagnostic and prognostic biosignatures to improve long-term outcomes in inflammatory bowel disease (IBD). Here, we describe the establishment of the Swedish Inception Cohort in IBD (SIC-IBD) and demonstrate its potential for the identification of such signatures.
Participants: Patients aged >= 18 years with gastrointestinal symptoms who were referred to the gastroenterology unit due to suspected IBD at eight Swedish hospitals between November 2011 and March 2021 were eligible for inclusion.
Findings to date: In total, 367 patients with IBD (Crohn's disease, n=142; ulcerative colitis, n=201; IBD-unclassified, n=24) and 168 symptomatic controls were included. In addition, 59 healthy controls without gastrointestinal symptoms were recruited as a second control group. Biospecimens and clinical data were collected at inclusion and in patients with IBD also during follow-up to 10 years. Levels of faecal calprotectin and high-sensitivity C-reactive protein were higher in patients with IBD compared with symptomatic controls and healthy controls. Preliminary results highlight the potential of serum protein signatures and autoantibodies, as well as results from faecal markers, to differentiate between IBD and symptomatic controls in the cohort. During the first year of follow-up, 37% (53/142) of the patients with Crohn's disease, 24% (48/201) with ulcerative colitis and 4% (1/24) with IBD-U experienced an aggressive disease course.
Future plans: We have established an inception cohort enabling ongoing initiatives to collect and generate clinical data and multi-omics datasets. The cohort will allow analyses for translation into candidate biosignatures to support clinical decision-making in IBD. Additionally, the data will provide insights into mechanisms of disease pathogenesis.
Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2025
Keywords
Inflammatory bowel disease, GASTROENTEROLOGY, Prognosis
National Category
Gastroenterology and Hepatology
Identifiers
urn:nbn:se:oru:diva-121187 (URN)10.1136/bmjopen-2025-099218 (DOI)001483484200001 ()40328654 (PubMedID)2-s2.0-105004588747 (Scopus ID)
Funder
Swedish Foundation for Strategic Research, RB13-0160Swedish Research Council, 2020-02021
Note
This work was supported by the Swedish Foundation for Strategic Research [RB13-0160 to JH], the Swedish Research Council [2020-02021 to JH], and the Örebro University Hospital research foundation [OLL-962042, OLL-974710, OLL-986849, OLL-1001470 to JH].
2025-05-222025-05-222025-10-30Bibliographically approved